ERBB2 and breast cancer: Among the 121 patients with advanced breast cancer included, all were female and the median age at primary disease diagnosis was 57 years (range 31–81); 28.1% of the patients were diagnosed with luminal A breast cancer (n = 34), 43.8% with luminal B (n = 53), 14.1% with HER2 + (n = 17) and 14% with TNBC (n = 17).